Multimodal treatment of gastric cancer

Moehler, Markus; Galle, Peter R.; Gockel, Ines; Junginger, Theodor; Schmidberger, Heinz

doi:10.1016/j.bpg.2007.10.003

Cited by 35 publications

(15 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Complete R0 resection and negative lymph nodes are the most important factors for long term survival. The majority of patients with gastric cancer eventually become palliative cases [5,19,26].…”

Section: The Current Situation Of Patients With Incurable Gastric Carmentioning

confidence: 99%

“…The range of recommendations for palliative surgical treatment is wide. Some authors recommend to perform surgical treatment only in those cases where severe tumor-related complications or symptoms are evident and interventional options have failed [18,19]. Other authors proposed that primary palliative resections should be performed whenever technically possible [14].…”

Section: The Current Situation Of Patients With Incurable Gastric Carmentioning

confidence: 99%

“…Numerous authors reported about prolongation of the survival time, improvement of the quality of life, and symptom relief and, therefore, supported palliative gastric resection. Other investigators presented limited retrospective data and recommended gastric resection only in cases of otherwise not controllable complications, such as tumor bleeding or organ perforation [18,19].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Non-curative gastric resection for patients with stage 4 gastric cancer—a single center experience and current review of literature

Dittmar

Rauchfuß

Goetz

et al. 2012

Langenbecks Arch Surg

View full text Add to dashboard Cite

show abstract

Section: The Current Situation Of Patients With Incurable Gastric Carmentioning

confidence: 99%

Section: The Current Situation Of Patients With Incurable Gastric Carmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Non-curative gastric resection for patients with stage 4 gastric cancer—a single center experience and current review of literature

Dittmar

Rauchfuß

Goetz

et al. 2012

Langenbecks Arch Surg

View full text Add to dashboard Cite

show abstract

“…It is especially prescribed for testicular, ovarian, bladder, liver, lung, and stomach cancers (1)(2)(3)(4)(5). DDP mediates its cytotoxic effects by binding to DNA, forming the intrastrand crosslinks and thus causing an inhibition of DNA synthesis and repair with eventual cell death (6,7).…”

mentioning

confidence: 99%

Functional Interactions of Cu-ATPase ATP7B with Cisplatin and the Role of ATP7B in the Resistance of Cells to the Drug

Leonhardt

Gebhardt

Mössner

et al. 2009

Journal of Biological Chemistry

View full text Add to dashboard Cite

Cisplatin is a widely used chemotherapeutic agent for treatment of ovarian, testicular, lung, and stomach cancers. The initial response to the drug is robust; however, tumor cells commonly develop resistance to cisplatin, which complicates treatment. Recently, overexpression of the Cu-ATPase ATP7B in ovary cells was linked to the increased cellular resistance to cisplatin; and the role for Cu-ATPases in the export of cisplatin from cells was proposed. Our results support functional interactions between cisplatin and ATP7B but argue against the active transport through the copper translocation pathway as a mechanism of drug resistance. In hepatocytes, we observed no correlation between the levels of endogenous ATP7B and the resistance of cells to cisplatin. Unlike copper, cisplatin does not induce trafficking of ATP7B in hepatoma cells, neither does it compete with copper in a transport assay. However, cisplatin binds to ATP7B and stimulates catalytic phosphorylation with EC 50 similar to that of copper. Mutations of the first five N-terminal copper-binding sites of ATP7B do not inhibit the cisplatin-induced phosphorylation of ATP7B. In contrast, the deletion of the first four copper-binding sites abolishes the effect of cisplatin on the ATP7B activity. Thus, cisplatin binding to ATP7B and/or general changes in cellular copper homeostasis are likely contributors to the increased resistance to the drug. The link between changes in copper homeostasis and cisplatin resistance was confirmed by treating the Huh7 cells with copper chelator and increasing their resistance to cisplatin. Cisplatin, cis-diamminedichloroplatinum (DDP),3 is a common anti-tumor agent that is used to treat many types of cancer. It is especially prescribed for testicular, ovarian, bladder, liver, lung, and stomach cancers (1-5). DDP mediates its cytotoxic effects by binding to DNA, forming the intrastrand crosslinks and thus causing an inhibition of DNA synthesis and repair with eventual cell death (6, 7). The initial tumor response to the treatment with DDP is robust; however, the efficacy of treatment decreases with longer and repetitive therapy cycles. The resistance arises rapidly and is sufficient to cause a failure of DDP therapy (8). The mechanisms by which cells develop resistance to DDP are not fully understood. Detoxification of DDP, enhanced repair and tolerance of DNA adducts, inhibition of apoptosis, impaired uptake and increased efflux of the drug may contribute to the acquired resistance of cells (9 -13).Recently, an unexpected connection was discovered between the resistance of cells to DDP and cellular copper metabolism (14 -16). Either down-regulation of CTR1 (49), a transporter responsible for the uptake of copper, and/or up-regulation of the copper-transporting ATPases (Cu-ATPases) responsible for copper efflux were found to increase cells resistance to DDP, although correlation between the levels of CTR1 and resistance were not always observed (17). The DDP-resistant cells were shown to have a lower copper content (18), and...

show abstract

“…In the US, gastric cancer mortality rates per 100,000 among males declined from 46.3 in 1930 to 5.9 in 2004, and the rates among females declined from 35.2 in 1930 to 3.0 in 2004 5,6 Nonetheless, gastric cancer remains a highly fatal condition, because the majority of patients are diagnosed with late-stage disease that is difficult to treat. 7,8 Previous studies have demonstrated that AI/AN populations are at higher risk for this disease than the general US population. 9,10 In the Southwestern US and in Alaska, incidence rates for gastric cancer among AI/AN populations remain high despite declining rates in other racial/ethnic populations from the same regions.…”

mentioning

confidence: 99%

Gastric cancer among American Indians and Alaska Natives in the United States, 1999-2004

Wiggins

Espey

Wingo

et al. 2008

Cancer

View full text Add to dashboard Cite

Multimodal treatment of gastric cancer

Cited by 35 publications

References 76 publications

Non-curative gastric resection for patients with stage 4 gastric cancer—a single center experience and current review of literature

Non-curative gastric resection for patients with stage 4 gastric cancer—a single center experience and current review of literature

Functional Interactions of Cu-ATPase ATP7B with Cisplatin and the Role of ATP7B in the Resistance of Cells to the Drug

Gastric cancer among American Indians and Alaska Natives in the United States, 1999-2004

Contact Info

Product

Resources

About